Switching to a lower-cost asthma and hives medication: tracking real-world outcomes

This study watches what happens when adults with severe asthma or chronic hives switch from their current biologic treatment to Omlyclo, a newer and more affordable version of omalizumab. Researchers want to make sure the medication works just as well after the switch and that patients stay satisfied with their treatment.

Biologic medications are very expensive and strain healthcare systems. When patents expire, cheaper versions called biosimilars are developed to provide the same benefits at lower cost. This study exists to confirm that this medication is just as safe and effective as the original version in real-world use, so more patients can access affordable treatment.